-+ 0.00%
-+ 0.00%
-+ 0.00%

GlaxoSmithKline agreed to buy an experimental hematologic cancer drug from a Chinese biotech company for up to 750 million US dollars to continue to enrich its expanding oncology pipeline. The British pharmaceutical company said in a statement on Tuesday that it will conduct multiple myeloma treatment tests on this drug purchased from the unlisted company Enmu Biotech and begin early clinical trials next year.

Zhitongcaijing·09/15/2026 07:33:07
Listen to the news
GlaxoSmithKline agreed to buy an experimental hematologic cancer drug from a Chinese biotech company for up to 750 million US dollars to continue to enrich its expanding oncology pipeline. The British pharmaceutical company said in a statement on Tuesday that it will conduct multiple myeloma treatment tests on this drug purchased from the unlisted company Enmu Biotech and begin early clinical trials next year.